Establishment Labs Holdings Inc. (ESTA) - What Are Researchers Saying About This Stock?

Key Points

• Analyst sentiment is generally positive: Establishment Labs has a “Moderate Buy” consensus, with nine buy ratings and one sell rating. The average 12-month price target is $98.56, although targets range from $85 to $117.
• Institutional ownership is substantial: Major investors including BlackRock, William Blair Investment Management and Bank of America recently acquired stakes, while institutions collectively own 72.91% of the company’s stock.
• Revenue growth remains strong but profitability is weak: Quarterly revenue rose 31.7% year over year to $67.54 million, exceeding estimates, but the company missed EPS expectations and remains loss-making, with analysts projecting a full-year loss of $1.15 per share.

Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report) has been given a consensus rating of "Moderate Buy" by the ten analysts that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and nine have assigned a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $98.56.

A number of brokerages have recently weighed in on ESTA. BTIG Research reaffirmed a "buy" rating and issued a $103.00 price target on shares of Establishment Labs in a research note on Tuesday, September 1st. Weiss Ratings reiterated a "sell (e+)" rating on shares of Establishment Labs in a research note on Monday, September 21st. TD Cowen reiterated a "buy" rating and set a $117.00 price objective on shares of Establishment Labs in a research note on Thursday. Stifel Nicolaus set a $85.00 target price on Establishment Labs and gave the stock a "buy" rating in a report on Wednesday. Finally, JPMorgan Chase & Co. upped their target price on Establishment Labs from $84.00 to $95.00 and gave the stock an "overweight" rating in a research report on Friday, August 7th.

Institutional Trading of Establishment Labs

Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. acquired a new stake in shares of Establishment Labs in the second quarter valued at $135,752,000. William Blair Investment Management LLC bought a new stake in Establishment Labs in the second quarter worth about $61,273,000. Bank of America Corp DE bought a new stake in Establishment Labs in the second quarter worth about $52,176,000. Rice Hall James & Associates LLC acquired a new stake in Establishment Labs in the 2nd quarter valued at about $48,134,000. Finally, Nantahala Capital Management LLC acquired a new stake in Establishment Labs in the 2nd quarter valued at about $28,817,572. Institutional investors own 72.91% of the company's stock.

Establishment Labs Stock Performance

ESTA stock opened at $61.36 on Friday. The company has a market capitalization of $1.83 billion, a P/E ratio of -46.84 and a beta of 1.06. The company has a 50-day simple moving average of $69.66 and a 200 day simple moving average of $74.47. Establishment Labs has a fifty-two week low of $44.26 and a fifty-two week high of $97.59. The company has a quick ratio of 2.52, a current ratio of 3.84 and a debt-to-equity ratio of 12.11.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.05). The company had revenue of $67.54 million during the quarter, compared to the consensus estimate of $65.79 million. Establishment Labs had a negative net margin of 15.82% and a negative return on equity of 196.69%. The business's quarterly revenue was up 31.7% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.57) EPS. Sell-side analysts predict that Establishment Labs will post -1.15 earnings per share for the current fiscal year.

About Establishment Labs

Establishment Labs Holdings Inc NASDAQ: ESTA is a medical technology company focused on women's health and breast aesthetics. The company develops, manufactures and markets medical devices intended for breast augmentation, reconstruction and related procedures.

Its principal product portfolio includes Motiva breast implants, a line of silicone-gel implants designed for aesthetic and reconstructive applications, as well as tissue expanders and other products used in breast surgery. Establishment Labs also offers Mia Femtech, a technology and procedure platform designed to support a less invasive approach to breast augmentation.

Founded in 2004, Establishment Labs is headquartered in Costa Rica and serves healthcare providers and patients in international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.